Brief summary :
Study to assess the potential effects of lurbinectedin (PM01183) at a therapeutic dose on the duration of the QTc interval, measured by electrocardiograms (ECGs), to characterize the PM01183 plasma concentration/QTc relationship, and to explore related ECG parameters in patients with selected solid tumors.
Recruitment Information :
Status : Recruiting
Start date : 2015-08
Primary completion date : 2016-06 (Anticipated) .
Administrative Data :
Organization name : PharmaMar
Organization study ID : PM1183-B-005-14-QT
Sponsor : PharmaMar
Health Authority United States : Food and Drug Administration .
...